Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Krishna Komanduri

Hematology & Oncology Miami, FL Medical Doctor

NPI 1598850265 CMS profile 72537

1475 Nw 12Th Ave, Miami, FL 33136

Open in the dashboard

General payments

$187,229

143 records reported · program years 2019–2025

Research payments

$13,521

Paid to them · 2 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Krishna Komanduri of Miami, FL is reported in the CMS Open Payments database as having received $187,229 across 143 general payments and $13,521 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Hematology & Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $29,607 16
2024 General $32,133 27
2023 General $25,474 32
2023 Research $5,071 1
2022 General $12,015 12
2021 General $38,710 8
2021 Research $8,450 1
2020 General $16,213 7
2019 General $33,077 41

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Krishna Komanduri
  • Hematology & Oncology median
  • Middle half of Hematology & Oncology
  • National median

In program year 2025, general payments to Krishna Komanduri were reported at $29,607. Among 8,769 Hematology & Oncology profiles paid that year, the median was $683 and the middle half received between $143 and $3,154.

Show as a table
Year Krishna Komanduri Hematology & Oncology median Middle half National median
2019 $33,077 $529 $121–$2,516 $163
2020 $16,213 $339 $82–$2,213 $114
2021 $38,710 $263 $49–$1,965 $132
2022 $12,015 $416 $103–$2,395 $149
2023 $25,474 $542 $125–$2,646 $160
2024 $32,133 $692 $141–$3,008 $164
2025 $29,607 $683 $143–$3,154 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Incyte Corporation $67,309 77 payments
  2. Kite Pharma, Inc. $31,873 20 payments
  3. Sanofi-Aventis U.S. LLC $14,688 8 payments
  4. Genzyme Corporation $14,376 2 payments
  5. Genentech, Inc. $14,040 2 payments
  6. Janssen Scientific Affairs, LLC $9,360 1 payment
  7. Novartis Pharmaceuticals Corporation $9,074 7 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $8,860 2 payments
  9. E.R. Squibb & Sons, L.L.C. $6,891 3 payments
  10. Janssen Biotech, Inc. $3,190 3 payments
  11. Other $7,567 18 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $160,107 32 payments
  2. Travel and Lodging $15,247 50 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $5,800 1 payment
  4. Food and Beverage $4,020 59 payments
  5. Honoraria $2,055 1 payment
Products named General payments · program years 2019–2025
  1. NIKTIMVO $12,341 12 payments
  2. JAKAFI $10,255 10 payments
  3. Yescarta Cellt $9,373 5 payments
  4. Yescarta Onc $9,372 7 payments
  5. KYMRIAH $8,512 5 payments
  6. REZUROCK $4,074 3 payments
  7. Rezlidhia $2,245 3 payments
  8. Tavalisse $2,245 3 payments
  9. CARVYKTI $2,030 2 payments
  10. JYNARQUE $25 1 payment
  11. Other $29 2 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Takeda Pharmaceuticals U.S.A., Inc. $8,450 1 payment
  2. F. Hoffmann-La Roche AG $5,071 1 payment

Records

145 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Hematology & Oncology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record